Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,410,560
  • Shares Outstanding, K 5,559,929
  • Annual Sales, $ 53,647 M
  • Annual Income, $ 11,152 M
  • 60-Month Beta 0.64
  • Price/Sales 4.46
  • Price/Cash Flow 10.23
  • Price/Book 4.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.77
  • Number of Estimates 4
  • High Estimate 0.81
  • Low Estimate 0.75
  • Prior Year 0.81
  • Growth Rate Est. (year over year) -4.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.01 +1.81%
on 07/12/19
44.56 -4.02%
on 07/03/19
-0.73 (-1.68%)
since 06/19/19
3-Month
38.81 +10.20%
on 04/22/19
44.56 -4.02%
on 07/03/19
+3.39 (+8.61%)
since 04/18/19
52-Week
37.12 +15.22%
on 07/20/18
46.47 -7.96%
on 12/04/18
+5.41 (+14.48%)
since 07/19/18

Most Recent Stories

More News
Anti-Epileptic Drugs For Pediatrics Market: Newer Drug Therapies With Symptom Specific Indications

Anti-epileptics drugs for pediatrics treatment are expected to experience visible shifts in terms of demand and adoption owing to factors such as rise in global prevalence of epilepsy, increasing healthcare...

VRX.TO : 30.80 (-3.33%)
NVS : 93.56 (-0.74%)
GSK : 40.96 (-1.09%)
PFE : 42.77 (-0.67%)
Pain Management Drugs Market to Represent A Significant Expansion $77,131 Million By 2023

accounted for $58,577 million in 2016, and is estimated to reach $77,131 million by 2023, registering a CAGR of 4% from 2017 to 2023. North America was the highest contributor to the pain management drugs...

SRNE : 2.60 (+0.78%)
VRX.TO : 30.80 (-3.33%)
BAYRY : 16.7400 (+0.51%)
ABT : 87.49 (-0.31%)
MRK : 81.39 (-1.57%)
LLY : 106.79 (-1.43%)
PFE : 42.77 (-0.67%)
BMY : 43.33 (-1.63%)
Allergan Announces FDA Acceptance of Glaucoma Candidate NDA

The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.

AERI : 23.12 (-2.12%)
AGN : 163.16 (+0.68%)
PFE : 42.77 (-0.67%)
OCUL : 4.56 (-6.17%)
Global pain management drugs market Industry Analysis and Forecast (2018-2026)

Global pain management drugs market was valued US$ 35.2 Bn in 2017 and is expected to reach US$ 52.6 Bn by 2026, at a CAGR of 5.15% during a forecast period.Pain management is the medical field used for...

VRX.TO : 30.80 (-3.33%)
LLY : 106.79 (-1.43%)
GSK : 40.96 (-1.09%)
PFE : 42.77 (-0.67%)
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, Danaher, Tesla and Cintas

The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, Danaher, Tesla and Cintas

TSLA : 258.18 (+1.83%)
BRK.B : 205.97 (-0.97%)
CTAS : 257.85 (-1.07%)
PFE : 42.77 (-0.67%)
DHR : 141.61 (-0.97%)
Should You Pick Up Novartis (NVS) Before Q2 Earnings?

Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should...

CRSP : 49.04 (-1.37%)
RCDTF : 34.7000 (-0.48%)
VRTX : 174.13 (-2.22%)
GBT : 55.56 (-3.36%)
ALC : 60.08 (-1.35%)
NVS : 93.56 (-0.74%)
PFE : 42.77 (-0.67%)
Pfizer (PFE) Gains As Market Dips: What You Should Know

Pfizer (PFE) closed at $42.86 in the latest trading session, marking a +0.25% move from the prior day.

PFE : 42.77 (-0.67%)
Top Research Reports for Berkshire Hathaway, Pfizer & Danaher

Top Research Reports for Berkshire Hathaway, Pfizer & Danaher

TSLA : 258.18 (+1.83%)
WELL : 83.05 (-2.12%)
BRK.B : 205.97 (-0.97%)
CTAS : 257.85 (-1.07%)
PFE : 42.77 (-0.67%)
DHR : 141.61 (-0.97%)
Nasal Drug Delivery Systems Market Is Estimated To Showcase Significant Growth Over 2028

The “Nasal Drug Delivery Systems Market: Worldwide Industrial Study, Size, Share, Growth, Trends, and Forecasts 2019–2028” report offers with all-inclusive, highly-efficient, and thoroughly analyzed...

VRX.TO : 30.80 (-3.33%)
NVS : 93.56 (-0.74%)
PFE : 42.77 (-0.67%)
ATR : 123.40 (-0.77%)
Stocks climb to records on hopes for lower interest rates

NEW YORK (AP) — The major U.S. stock indexes closed at record highs on Friday, with the S&P 500 ending above 3,000 for the first time. The market was driven higher by technology, consumer discretionary...

C : 70.92 (-1.21%)
WFC : 46.03 (+0.46%)
JPM : 113.54 (-0.99%)
JNJ : 130.31 (-1.33%)
LLY : 106.79 (-1.43%)
PFE : 42.77 (-0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade PFE with:

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

2nd Resistance Point 43.36
1st Resistance Point 43.06
Last Price 42.77
1st Support Level 42.62
2nd Support Level 42.48

See More

52-Week High 46.47
Fibonacci 61.8% 42.90
Last Price 42.77
Fibonacci 50% 41.79
Fibonacci 38.2% 40.69
52-Week Low 37.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar